Arcutis Biotherapeutics, Inc. Common Stock
ARQT Real Time Price USDRecent trades of ARQT by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ARQT holdings by institutional investors
Quarterly net insider trading by ARQT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for ARQT
7 former government officials from 6 congressional offices at 1 lobbying firm have lobbied for ARQT, most recently Sep 17, 2026.
-
John Ray House New Legislative Assistant, Rep. Mike Kelly -
Kristin Fritsch House New Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce -
Cooper Chamblee Senate New Intern, Sen. Tim Scott -
John Herzog Senate New Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President -
Brett Meeks Senate New Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander
-
Laura Kemper Senate New Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services -
Keith Studdard House New Legislative Director, Rep. Marsha Blackburn
ARQT Estimated quarterly lobbying spending
ARQT Revenue by Segment or Geography
New ARQT patent grants
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors Aug. 04, 2026
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors Jul. 21, 2026
-
Patent Title: Pharmaceutical compositions of spironolactone for deep dermal drug delivery Nov. 04, 2025
-
Patent Title: Topical roflumilast aerosol foams Oct. 28, 2025
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors Aug. 19, 2025
-
Patent Title: Inhibition of crystal growth of roflumilast Jun. 24, 2025
-
Patent Title: Topical roflumilast formulation having antifungal properties Jun. 17, 2025
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half-life May. 27, 2025
-
Patent Title: Inhibition of crystal growth of roflumilast Mar. 25, 2025
-
Patent Title: Roflumilast formulations with an improved pharmacokinetic profile Feb. 11, 2025
-
Patent Title: Stable formulations of shr0302 Dec. 10, 2024
-
Patent Title: Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug Nov. 19, 2024
-
Patent Title: Laureth-4 containing topical formulations Sep. 10, 2024
-
Patent Title: Compositions and methods for deep dermal drug delivery Aug. 06, 2024
-
Patent Title: Method and formulation for improving roflumilast skin penetration lag time Jul. 23, 2024
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors Jul. 23, 2024
-
Patent Title: Roflumilast formulations with an improved pharmacokinetic profile Jun. 25, 2024
-
Patent Title: Roflumilast formulations with an improved pharmacokinetic profile Jun. 18, 2024
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half-life Jun. 11, 2024
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half life Jun. 11, 2024
-
Patent Title: Method for reducing side effects from administration of phosphodiesterase-4 inhibitors May. 28, 2024
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half-life Nov. 21, 2023
-
Patent Title: Inhibition of crystal growth of roflumilast Oct. 24, 2023
-
Patent Title: Laureth-4 containing topical formulations Aug. 22, 2023
-
Patent Title: Topical roflumilast formulation having antifungal properties Jul. 25, 2023
-
Patent Title: Compositions and methods for deep dermal drug delivery Apr. 18, 2023
-
Patent Title: Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents Dec. 27, 2022
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half life Sep. 28, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ARQT from public contracts
Recent insights relating to ARQT
Recent picks made for ARQT stock on CNBC
ETFs with the largest estimated holdings in ARQT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ARQT stock a Buy, Sell, or Hold?
- What is the price target for $ARQT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ARQT stock?
- Who owns the most shares of $ARQT stock?
- What funds own $ARQT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ARQT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
- Address Westlake Village, CA
- Market Cap 3.4 billion
- Employees 354
- Industrial Classification Pharmaceutical Preparations
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Arcutis Biotherapeutics, Inc. Common Stock (ARQT).
Quiver Premium charts ARQT's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at ARQT, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|